APA (7th ed.) Citation

Schöffski, P., Tan, D. S., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., . . . Hong, D. S. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer, 10(2), . https://doi.org/10.1136/jitc-2021-003776

Chicago Style (17th ed.) Citation

Schöffski, Patrick, et al. "Phase I/II Study of the LAG-3 Inhibitor Ieramilimab (LAG525) ± Anti-PD-1 Spartalizumab (PDR001) in Patients with Advanced Malignancies." Journal for ImmunoTherapy of Cancer 10, no. 2 (2022). https://doi.org/10.1136/jitc-2021-003776.

MLA (9th ed.) Citation

Schöffski, Patrick, et al. "Phase I/II Study of the LAG-3 Inhibitor Ieramilimab (LAG525) ± Anti-PD-1 Spartalizumab (PDR001) in Patients with Advanced Malignancies." Journal for ImmunoTherapy of Cancer, vol. 10, no. 2, 2022, https://doi.org/10.1136/jitc-2021-003776.